Early postnatal treatment of hypogonadotropic hypogonadism with recombinant human FSH and LH

80 Citations (Scopus)


BACKGROUND: Patients with hypogonadotropic hypogonadism may be diagnosed shortly after birth because of micropenis and cryptorchidism, combined with subnormal LH and FSH concentrations during the postnatal period.

OBJECTIVE: To investigate whether treating these patients with gonadotropins postnatally, to mimic the physiological development, would improve testicular growth and fertility potential later in life.

DESIGN: Our patient presented with micropenis. Serum hormone concentrations were measured monthly after delivery: LH and testosterone were undetectable, and FSH and inhibin B were below the normal range (0.05-0.17 IU/l and 79-112 pg/ml respectively).

METHODS: From 7.9 to 13.7 months of age, the patient was treated with recombinant human LH and FSH in doses of 20 and 21.3 IU s.c. twice weekly respectively.

RESULTS: During treatment concentrations of LH, FSH, inhibin B and estradiol increased to values within normal limits (0.7-1.88 IU/l, 0.17-3.24 IU/l, 121-268 pg/ml and 40-55 pmol/l respectively), whereas serum testosterone remained undetectable. Penile length increased from 1.6 to 2.4 cm and testicular volume, assessed by ultrasound, increased by 170%. No significant adverse events were observed.

CONCLUSIONS: Gonadotropin treatment in an infant with hypogonadotropic hypogonadism succeeded in inducing an increase in inhibin B and testicular growth.

Original languageEnglish
JournalEuropean Journal of Endocrinology
Issue number1
Pages (from-to)75-9
Number of pages5
Publication statusPublished - Jan 2002


  • Follicle Stimulating Hormone
  • Gonadotropins
  • Hormone Replacement Therapy
  • Humans
  • Hypogonadism
  • Infant, Newborn
  • Inhibins
  • Injections, Subcutaneous
  • Luteinizing Hormone
  • Male
  • Recombinant Proteins
  • Reference Values
  • Testis
  • Ultrasonography
  • Case Reports
  • Journal Article


Dive into the research topics of 'Early postnatal treatment of hypogonadotropic hypogonadism with recombinant human FSH and LH'. Together they form a unique fingerprint.

Cite this